Development of Special Biological Products.
Abstract
Tissue culture: Three production lots of FRhL-2, one each of MRC-5 and primary Duck and two lots of A. albopictus (C6-36) were stabilized and frozen. Eight lots of cells for use in testing were processed. Vee (C-84) Vaccine Development: Potency testing on Lots C-84-6 and C-84-7 was completed. A second addendum covering VEE, inactivated, dried (TSI-GSD 205) vaccine lots C-84-2 through C-84-7 was prepared and transmitted to USAMRIID. WEE Vaccine Development: Testing of WEE vaccine seed virus, strain CM4884 was completed. A test for adventitous agents in the seed was negative. Rift Valley Fever Vaccine Development: The tests to certify the RVF virus, strain ZZ501, for vaccine production were completed. Junin Virus Vaccine Development: Safety tests on four fluids prepared at USAMRIID were conducted. Two freeze-drying runs using various suspending diluents were done. Korean Hemorrhagic Fever: A total of 20 lots of 10 spot FA slides were produced and shipped. Tularemia Vaccine Development: Three batches of tularemia vaccine bacteria, strain LVS, were produced in a fermentor.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1983
- Accession Number
- ADA150862
Entities
People
- A. Shelokov
- C. K. Lee
- D. E. Craig
- G. R. French
- J. L. Demeio